Effect of an herbal medicine, Chunghyul-dan, on prevention of recurrence in patients with ischemic stroke: A retrospective cohort study

Research indicates that Chunghyul-dan (CHD), a herbal medicine, has an inhibitory effect on stroke recurrence in small vessel disease. Recent studies have suggested that CHD might also act on large arteries. This study aimed to verify the preventive effect of CHD on strokes of all the Trial of Org 1...

Full description

Saved in:
Bibliographic Details
Published in:Medicine (Baltimore) 2023-11, Vol.102 (45), p.e35840-e35840
Main Authors: Lee, Han-Gyul, Kwon, Seungwon, Cho, Seung-Yeon, Park, Seong-Uk, Jung, Woo-Sang, Moon, Sang-Kwan, Park, Jung-Mi, Ko, Chang-Nam, Jang, Hyeung-Jin, Cho, Ki-Ho
Format: Article
Language:English
Subjects:
Atherosclerosis - complications
Brain Ischemia - complications
Brain Ischemia - drug therapy
Brain Ischemia - prevention & control
Humans
Ischemic Stroke - complications
Observational Study
Plant Extracts
Recurrence
Retrospective Studies
Risk Factors
Stroke - drug therapy
Stroke - etiology
Stroke - prevention & control
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Research indicates that Chunghyul-dan (CHD), a herbal medicine, has an inhibitory effect on stroke recurrence in small vessel disease. Recent studies have suggested that CHD might also act on large arteries. This study aimed to verify the preventive effect of CHD on strokes of all the Trial of Org 10172 in Acute Stroke Treatment (TOAST) causative classifications. We retrospectively analyzed 2 years of medical records of patients with ischemic stroke treated with CHD, 600 mg once daily, in combination with antiplatelet or anticoagulant agents. The prevalence of stroke recurrence in 2 years was analyzed. Stroke recurrence was defined as new neurological symptoms with corresponding brain imaging results. Nine of the 202 patients (4.46%) had recurrent ischemic stroke. Four occurred within 180 days, 3 between 180 and 365 days, and 2 between 365 and 730 days. All had only 1 recurrence. The recurrence rates were 1.12%, 5%, and 5.48% for small vessel occlusion, cardioembolism, and large vessel atherosclerosis, respectively. There were no adverse effects. These results suggest that CHD could inhibit ischemic stroke recurrence of all TOAST causative categories. A randomized controlled trial is needed to confirm this hypothesis.
ISSN:0025-7974
1536-5964
DOI:10.1097/MD.0000000000035840